Uprosertib (GSK2141795)

Catalog No.S7492 Synonyms: GSK795

For research use only.

Uprosertib (GSK2141795, GSK795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.

Uprosertib (GSK2141795) Chemical Structure

CAS No. 1047634-65-0

Selleck's Uprosertib (GSK2141795) has been cited by 10 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Akt Inhibitors

Other Akt Products

Biological Activity

Description Uprosertib (GSK2141795, GSK795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.
Targets
Akt3 [1]
(Cell-free assay)
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
38 nM 180 nM 328 nM
In vitro

Uprosertib inhibits multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in both BT474 and LNCaP cells. Uprosertib preferentially inhibits the proliferation of human cancer cells lines with AKT pathway activation. In LNCaP, BT474, A3 and I9.2 cells lines, Uprosertib also causes cell cycle arrest. [2] In both SKOV3 and PEO4 cells, Uprosertib causes growth-arrest as single agent, and enhances cisplatin-induced apoptosis. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OVCAR8 NYPOPFhPSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NEnWUJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTQCClZXzsd{whUUN3ME2wMlI1|ryP NF\O[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUK5PFU1Oid-M{GyPVg2PDJ:L3G+
Sf9 MV3GeY5kfGmxbjDhd5NigQ>? MV[0NEBucW6| M1;0VGlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5iQVvUNUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC|dXLzeJJifGVicHjvd5Bpd3K7bHH0bY9vKHW|aX7nJIJqd3Srbj3hbJguSVKNUlXSRXlUTkeKSFGtZY1q\GVic4Xid5Rz[XSnIHHu[EBc\2GvbXGtN|NRZUGWUDDpcoN2[mG2ZXSg[o9zKDRyIH3pcpMh[nlidH;wJINwfW62IH3pZ5JweGyjdHWgd4NqdnSrbHzheIlwdiClb4XueIlv\yCvZYToc4QtKEmFNUC9NE4xODF7OUZOwG0> NILrZ5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OTN5M{O2M{c,S2iHTVLMQE9iRg>?
JVM2 M2SzXmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MojmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCMVl2yJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUwhUUN3ME2wMlI6O87:TR?= Mn\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|MEG1OlUoRjNzM{CxOVY2RC:jPh?=
KB-3-1 Mlv0dWhVWyCjc4PhfS=> NWTiXotpWC2pbInjc5Bzd3SnaX6gd5Vje3S{YYTld{Bq\GWwdHnmbYVlKGmwIFvCMVMuOSCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoUtKHGKVGOgeIhmemGyZYX0bYMhdGmkcnHyfUB{[3KnZX6= NEHSfGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OTN5M{O2M{c,S2iHTVLMQE9iRg>?
HUT78 NH7adpFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVEe4JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUwhUUN3ME2wMlM4QM7:TR?= M1zm[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzM{CxOVY2Lz5|MUOwNVU3PTxxYU6=
Sf9 NYjMWnQ4TnWwY4Tpc44h[XO|YYm= NV\kSYJqPDBibXnudy=> M3P4UGlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5iQVvUNkBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC|dXLzeJJifGVicHjvd5Bpd3K7bHH0bY9vKHW|aX7nJIJqd3Srbj3hbJguSVKNUlXSRXlUTkeKSFGtZY1q\GVic4Xid5Rz[XSnIHHu[EBc\2GvbXGtN|NRZUGWUDDpcoN2[mG2ZXSg[o9zKDRyIH3pcpMh[nlidH;wJINwfW62IH3pZ5JweGyjdHWgd4NqdnSrbHzheIlwdiClb4XueIlv\yCvZYToc4QtKEmFNUC9NE4xOTV6Nd88US=> MoLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E{PzN|Nj:nQmNpTU2ETEyvZV4>
CEM/C1 NYqyTYw{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{Pjd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1XNM2MyKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSxiSVO1NF0xNjB|zszN MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTNyMUW2OUc,OzF|MEG1OlU9N2F-
RPMI8226 NUfE[ZhiSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKSTVm4NlI3KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSxiSVO1NF0xNjV|ON88US=> M1yyXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzM{CxOVY2Lz5|MUOwNVU3PTxxYU6=
MM1S MnjxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NX\1OYdDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNUVFUKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSxiSVO1NF0xNjB|Mt88US=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTNyMUW2OUc,OzF|MEG1OlU9N2F-
OVCAR8 NWT3b2dMS3m2b4TvfIlkcXS7IHHzd4F6 MnW2O|IhcHK| M4C4emN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwNUVOwG0> NEPqcmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUOwNVU3PSd-M{GzNFE2PjV:L3G+
MOLT4 NVTUTYptSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NVfXSYZKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHluIFnDOVA:OC5yNkdOwG0> NXPvUlRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNFE2PjVpPkOxN|AyPTZ3PD;hQi=>
MV4-11 MlS5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MljoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6NCCLQ{WwQVAvPjN3zszN NUHTT2dvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNFE2PjVpPkOxN|AyPTZ3PD;hQi=>
LNCAP MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NEfMZm5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzMEBKSzVyPUCuNFfPxE1? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJ7OEW0Nkc,OzF{OUi1OFI9N2F-
HCT116 NVi2XHRxSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mlr3O|IhcHK| MkG3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1yLkey{txO NH;FbYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUK5PFU1Oid-M{GyPVg2PDJ:L3G+
PTEN-null LNCAP M3LzfmZ2dmO2aX;uJIF{e2G7 MVqxJIhz MYrJcohq[mm2aX;uJI9nKEGtdDDpckBpfW2jbjDQWGVPNW63bHygUG5ESVBiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gbY4hWFKDU{SwJJBpd3OyaH;yfYxifGmxbjDh[pRmeiBzIHjyJIJ6KEWOSWPBJIFv[Wy7c3nzMEBKSzVyPUCuNFc2PjQQvF2= M3rCfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlEyLz5{N{C4PVIyOTxxYU6=
HCT116 NXW4VFNWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XhXlczKGi{cx?= MUTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncj3lfJBz\XO|aX7nJGRJV0SKIHH0JFIhfGmvZYOgZY51cXC{b3zp[oVz[XSrdnWgTWM2OCCjZoTldkA4OiCqcoOgbY4h[WK|ZX7j[UBw\iC3cnnkbY5mKGK7IF3UWEBie3OjeR?= M{PRb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzM{CxOVY2Lz5|MUOwNVU3PTxxYU6=
U937 Mli1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV7M{egZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5MEBKSzVyPUCuNVAy|ryP NE\GSVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUOwNVU3PSd-M{GzNFE2PjV:L3G+
OVCAR8 M1HBPWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4PTSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI5KGOnbHzzMEBKSzVyPUCuNlTPxE1? M16zVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMkm4OVQzLz5|MUK5PFU1OjxxYU6=
JVM2 MonPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEqYTUKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5MEBKSzVyPUCuNlk{|ryP Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|MEG1OlUoRjNzM{CxOVY2RC:jPh?=
HUT78 MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVEe4JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUwhUUN3ME2wMlM4QM7:TR?= NF;Te2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUOwNVU3PSd-M{GzNFE2PjV:L3G+
RPMI8226 M3LHN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4LvXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzOjZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7LDDJR|UxRTBwNUO4{txO MmrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|MEG1OlUoRjNzM{CxOVY2RC:jPh?=
OVCAR8 NW\qflRDS3m2b4TvfIlkcXS7IHHzd4F6 NYPG[4RvPzJiaILz Mm\zR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC53NN88US=> NXjXcHBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNFE2PjVpPkOxN|AyPTZ3PD;hQi=>
MV4-11 M1W4WGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Mn;FRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6NCCLQ{WwQVAvPjN3zszN Moj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|MEG1OlUoRjNzM{CxOVY2RC:jPh?=
HCT116 MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYj4PGk2PzJiaILz MoXQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1yLkey{txO MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJ7OEW0Nkc,OzF{OUi1OFI9N2F-
HCT116 NVrBXpZnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MknIO|IhcHK| NXLyOY0xT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZIu\XiycnXzd4lv\yCGSF;ETEBifCB{IITpcYV{KGGwdHnwdo9tcW[ncnH0bZZmKEmFNUCgZYZ1\XJiN{KgbJJ{KGmwIHHid4Vv[2Vib3[geZJq\GmwZTDifUBOXFRiYYPzZZk> NY[3[oZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNFE2PjVpPkOxN|AyPTZ3PD;hQi=>
In vivo In mice bearing BT474 breast tumor xenografts, Uprosertib (100 mg/kg, p.o.) results 61% tumor growth inhibition. In mice bearing SKOV3 ovarian tumor xenografts, Uprosertib (30 mg/kg, p.o.) results 61% tumor growth inhibition. [2]

Protocol (from reference)

Kinase Assay:[1]
  • Selectivity profiling experiments:

    The lysates (5 mg of total protein each) are preincubated with 0 (DMSO control), 2.5 nM, 25 nM, 250 nM, 2.5 μM or 25 μM free compound (GSK690693 or GSK2141795) on an end-over-end shaker for 45 min at 4 °C. Subsequently, lysates are incubated with beads (coupled Akt probe or kinobeads) for 1 h at 4 °C, for both qualitative and quantitative experiments. The beads are washed with 1× CP buffer and collected by centrifugation. Bound proteins are eluted with 2× NuPAGE LDS sample buffer, and eluates are reduced and alkylated by 50 mM dithiothreitol and 55 mM iodoacetamide.

Cell Research:[2]
  • Cell lines: A panel of 290 cells lines
  • Concentrations: ~30 μM
  • Incubation Time: 3 d
  • Method: Cell lines are typically grown in RPMI 160 medium containing 10% FBS. Some cell lines are grown in media specified by the vendor. A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0–30 µM. Cell growth is determined relative to untreated (DMSO) controls. EC50's are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application.
Animal Research:[2]
  • Animal Models: Mice bearing either BT474 or SKOV3 tumors
  • Dosages: 100 mg/kg
  • Administration: p.o.

Solubility (25°C)

In vitro

DMSO 85 mg/mL
(198.01 mM)
Water Insoluble
Ethanol '85 mg/mL

Chemical Information

Molecular Weight 429.25
Formula

C18H16Cl2F2N4O2

CAS No. 1047634-65-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)NC(CC3=CC(=C(C=C3)F)F)CN)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01958112 Terminated Drug: GSK1120212 (trametinib)|Drug: GSK2141795 Cervical Cancer Dana-Farber Cancer Institute|Novartis|National Comprehensive Cancer Network October 2013 Phase 2
NCT01941927 Completed Drug: Trametinib (GSK1120212)|Drug: GSK2141795 Melanoma Adil Daud|National Comprehensive Cancer Network|University of California San Francisco September 10 2013 Phase 2
NCT01266954 Completed Drug: GSK2141795 Solid Tumours GlaxoSmithKline June 1 2010 Phase 1
NCT01138085 Completed Drug: GSK1120212|Drug: GSK2141795 Cancer GlaxoSmithKline May 4 2010 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Uprosertib (GSK2141795) | Uprosertib (GSK2141795) supplier | purchase Uprosertib (GSK2141795) | Uprosertib (GSK2141795) cost | Uprosertib (GSK2141795) manufacturer | order Uprosertib (GSK2141795) | Uprosertib (GSK2141795) distributor